METHODS A group of 8 experts on the management of schizophrenia and LAIs met to
evaluate the evidence and to develop a set of recommendations regarding the clinical use …

Introduction Maintenance antipsychotic treatment improves multiple outcomes in people with
schizophrenia. These benefits are challenged by medication nonadherence, which is a …

In 2009 the WPA President established a Task Force that was to examine available
evidence about the stigmatization of psychiatry and psychiatrists and to make …

Psychiatrists' attitudes and knowledge about antipsychotic long-acting injections (LAIs) are
important given the increasing emphasis on patient choice in treatment and the availability …

BackgroundThe attitudes of staff and patients have been demonstrated to influence the
acceptance of long-acting injections (LAIs) or depot antipsychotics. AimsTo examine the …

Introduction The importance of stigma toward patients with mental illness in medical
students as future physicians cannot be overemphasized. There is currently no formal …

Objective: Nonadherence for first-episode schizophrenia is a major unsolved challenge. The
long-acting injectable route is an appealing strategy, but there are concerns about …

Long-acting depot antipsychotics were developed specifically to promote treatment
adherence (compliance) and they are a valuable option for patients requiring maintenance …

Importance of the field: Antipsychotic medications are the cornerstone of treatment in
schizophrenia, and a large body of data confirms the value of ongoing and continuous …

Long-acting injectable (depot) antipsychotics are one approach in the management of
individuals with schizophrenia. Since the introduction of risperidone long-acting injection in …